|Rapid Review Complete
|For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
|Rapid review commissioned
|Rapid review resubmission required
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ritlecitinib compared with the current standard of care.